Key Structural and Operational Considerations for Biosimilar Adoption

Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

Now Viewing

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

EP: 6.Positioning Biosimilars in Clinical Practice

EP: 7.Assessing Patient Confidence With Biosimilars

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

Video content above is prompted by the following:

• When health care systems move to biosimilar adoption, what are the key structural and operational considerations that go into this transition?

Related Videos

Related Content

Advertisement

March 21st 2025

Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics

Jared Kaltwasser

Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 19th 2025

Social Media Insights Shed Light on Patient Experiences With Uncomplicated UTIs

Brooke McCormick

To better understand patient experiences, the researchers analyzed qualitative and quantitative data from their social media posts about uncomplicated urinary tract infections (UTIs).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 19th 2025

EMBARK Data Show Continued Improvements With DMD Gene Therapy

Christina Mattina

Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.

March 18th 2025

Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic

Christina Mattina

The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.

Related Content

Advertisement

March 21st 2025

Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics

Jared Kaltwasser

Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 19th 2025

Social Media Insights Shed Light on Patient Experiences With Uncomplicated UTIs

Brooke McCormick

To better understand patient experiences, the researchers analyzed qualitative and quantitative data from their social media posts about uncomplicated urinary tract infections (UTIs).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 19th 2025

EMBARK Data Show Continued Improvements With DMD Gene Therapy

Christina Mattina

Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.

March 18th 2025

Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic

Christina Mattina

The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.